Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00678730 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacogenetics of Cannabinoid Response
A Early Phase 1 study of COMT Gene Polymorphism, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT00678730: Completed Early Phase 1 study of COMT Gene Polymorphism, sponsored by Yale University.
NCT00678730 is a Early Phase 1 study of COMT Gene Polymorphism that has completed, run by Yale University. The registered enrollment target is 72 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (36% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00678730, a Early Phase 1 study of COMT Gene Polymorphism, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This study attempts to examine genetic influences on the effects of tetrahydrocannabinol (Δ9-THC), the active ingredient of marijuana, cannabis, "ganja", or "pot".
Conditions Studied
Interventions
- DRUG delta 9 tetrahydrocannabinol
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2007-08-23 |
| Est. Completion | 2014-09-11 |
| Phase | Early Phase 1 |
What the finished NCT00678730 record still lists
NCT00678730 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (36% higher).
The record links to 1 condition, with COMT Gene Polymorphism appearing as the primary indexed condition, and to 1 intervention - of which delta 9 tetrahydrocannabinol is the first listed.
NCT00678730 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00678730 about?
NCT00678730 is a clinical study titled "Pharmacogenetics of Cannabinoid Response". This study attempts to examine genetic influences on the effects of tetrahydrocannabinol (Δ9-THC), the active ingredient of marijuana, cannabis, "ganja", or "pot".
What is the current status of trial NCT00678730?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 72 participants. The study started on 2007-08-23. Estimated completion is 2014-09-11.
What conditions does trial NCT00678730 study?
This clinical trial studies the following conditions: COMT Gene Polymorphism.
What interventions are being tested in trial NCT00678730?
The interventions under investigation include: delta 9 tetrahydrocannabinol (DRUG).
Who is sponsoring clinical trial NCT00678730?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00678730 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00678730's enrollment target sits among peer trials
72 319th of 2000 higher than 1,674 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI